RPG Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
February 01, 2023 at 07:03 am
Share
RPG Life Sciences Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 1,306 million compared to INR 1,155.8 million a year ago. Revenue was INR 1,311.1 million compared to INR 1,161.9 million a year ago. Net income was INR 191.1 million compared to INR 146.3 million a year ago. Basic earnings per share from continuing operations was INR 11.56 compared to INR 8.85 a year ago. Diluted earnings per share from continuing operations was INR 11.56 compared to INR 8.85 a year ago.
For the nine months, sales was INR 3,943.2 million compared to INR 3,363.6 million a year ago. Revenue was INR 3,972.8 million compared to INR 3,380.9 million a year ago. Net income was INR 572.9 million compared to INR 439.6 million a year ago. Basic earnings per share from continuing operations was INR 34.64 compared to INR 26.58 a year ago. Diluted earnings per share from continuing operations was INR 34.64 compared to INR 26.58 a year ago.
RPG Life Sciences Limited is an India-based pharmaceutical company. The Company operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes domestic formulations, international formulations and APIs. Its domestic formulation business manufactures and markets branded finished dosage formulations in India. The domestic formulations business has presence in over 10 therapeutic areas, including nephrology, oncology, rheumatology, cardiology, respiratory, nutritional, gastroenterology, and diabetology, among others. The international formulations business is involved in developing, manufacturing and marketing oral solid formulations in the generic and branded generic space across regulated and emerging markets. Its products include Azoran, Mofetyl, Arpimune ME, Azathioprine, Sodium Valproate PR, Nicorandil, Quinfamide, Nicorandil, Haloperidol, Risperidone, and others.